Literature DB >> 16433871

Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery.

Christine E Staatz1, Colette Byrne, Alison H Thomson.   

Abstract

AIMS: To describe the population pharmacokinetics of gentamicin and vancomycin in cardiothoracic surgery patients with unstable renal function.
METHODS: Data collected during routine care were analyzed using NONMEM. Linear relationships between creatinine clearance (CL(Cr)) and drug clearance (CL) were identified, and two approaches to modelling changing CL(Cr) were examined. The first included baseline (BCOV) and difference from baseline (DCOV) effects and the second allowed the influence of CL(Cr) to vary between individuals. Final model predictive performance was evaluated using independent data. The data sets were then combined and parameters re-estimated.
RESULTS: Model building was performed using data from 96 (gentamicin) and 102 (vancomycin) patients, aged 17-87 years. CL(Cr) ranged from 9 to 172 ml min(-1) and changes varied from -76 to 58 ml min(-1) (gentamicin) and -86 to 93 ml min(-1) (vancomycin). Inclusion of BCOV and DCOV improved the fit of the gentamicin data but had little effect on that for vancomycin. Inclusion of interindividual variability (IIV) in the influence of CL(cr) resulted in a poorly characterized model for gentamicin and had no effect on vancomycin modelling. No bias was seen in population compared with individual CL estimates in independent data from 39 (gentamicin) and 37 (vancomycin) patients. Mean (95% CI) differences were 4% (-3, 11%) and 2% (-2, 6%), respectively. Final estimates were: CL(Gent) (l h(-1)) = 2.81 x (1 + 0.015 x (BCOV(CLCr)-BCOV(CLCr Median)) + 0.0174 x DCOV(CLCr)); CL(Vanc) (l h(-1)) = 2.97 x (1 + 0.0205 x (CL(Cr)-CL(Cr Median))). IIV in CL was 27% for both drugs.
CONCLUSIONS: A parameter describing individual changes in CL(cr) with time improves population pharmacokinetic modelling of gentamicin but not vancomycin in clinically unstable patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16433871      PMCID: PMC1885003          DOI: 10.1111/j.1365-2125.2005.02547.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.

Authors:  Ulrika Wählby; Alison H Thomson; Peter A Milligan; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

2.  Population pharmacokinetics of vancomycin in Japanese adult patients.

Authors:  M Yasuhara; T Iga; H Zenda; K Okumura; T Oguma; Y Yano; R Hori
Journal:  Ther Drug Monit       Date:  1998-04       Impact factor: 3.681

3.  Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group.

Authors:  C M Mangano; L S Diamondstone; J G Ramsay; A Aggarwal; A Herskowitz; D T Mangano
Journal:  Ann Intern Med       Date:  1998-02-01       Impact factor: 25.391

Review 4.  Gentamicin dosing in critically ill patients.

Authors:  M Hansen; L L Christrup; J O Jarløv; J P Kampmann; J Bonde
Journal:  Acta Anaesthesiol Scand       Date:  2001-07       Impact factor: 2.105

5.  Renal pathological findings in infective endocarditis.

Authors:  A Majumdar; S Chowdhary; M A Ferreira; L A Hammond; A J Howie; G W Lipkin; W A Littler
Journal:  Nephrol Dial Transplant       Date:  2000-11       Impact factor: 5.992

6.  Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen.

Authors:  Roger Jelliffe
Journal:  Am J Nephrol       Date:  2002 Jul-Aug       Impact factor: 3.754

7.  Experience with a once-daily dosing program of aminoglycosides in critically ill patients.

Authors:  S E Buijk; J W Mouton; I C Gyssens; H A Verbrugh; H A Bruining
Journal:  Intensive Care Med       Date:  2002-05-30       Impact factor: 17.440

8.  The use of a change in gentamicin clearance as an early predictor of gentamicin-induced nephrotoxicity.

Authors:  Carl M J Kirkpatrick; Stephen B Duffull; Evan J Begg; Chris Frampton
Journal:  Ther Drug Monit       Date:  2003-10       Impact factor: 3.681

9.  Population pharmacokinetics of gentamicin in patients with cancer.

Authors:  M C Rosario; A H Thomson; D I Jodrell; C A Sharp; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

Review 10.  Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines.

Authors:  A Burton; D G Altman
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

View more
  14 in total

Review 1.  Vancomycin: a review of population pharmacokinetic analyses.

Authors:  Amélie Marsot; Audrey Boulamery; Bernard Bruguerolle; Nicolas Simon
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery.

Authors:  Iona Macdonald; Christine E Staatz; Roger W Jelliffe; Alison H Thomson
Journal:  Ther Drug Monit       Date:  2008-02       Impact factor: 3.681

3.  Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model.

Authors:  Khaled Abduljalil; Masoud Jamei; Amin Rostami-Hodjegan; Trevor N Johnson
Journal:  AAPS J       Date:  2014-04-04       Impact factor: 4.009

4.  Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens.

Authors:  Wei-Wei Lin; Wei Wu; Zheng Jiao; Rong-Fang Lin; Chang-Zhen Jiang; Pin-Fang Huang; Yi-Wei Liu; Chang-Lian Wang
Journal:  Eur J Clin Pharmacol       Date:  2015-10-01       Impact factor: 2.953

5.  Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.

Authors:  Natalia Revilla; Ana Martín-Suárez; Marta Paz Pérez; Félix Martín González; María Del Mar Fernández de Gatta
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

6.  The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults.

Authors:  Didi Bury; Rob Ter Heine; Ewoudt M W van de Garde; Marten R Nijziel; Rene J Grouls; Maarten J Deenen
Journal:  Eur J Clin Pharmacol       Date:  2019-03-15       Impact factor: 2.953

7.  Comparison of the Predictive Performance Between Cystatin C and Serum Creatinine by Vancomycin via a Population Pharmacokinetic Models: A Prospective Study in a Chinese Population.

Authors:  Ren Zhang; Ming Chen; Tao-Tao Liu; Jie-Jiu Lu; Chun-le Lv
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-02       Impact factor: 2.441

8.  Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study.

Authors:  Elisabet I Nielsen; Marie Sandström; Per Hartvig Honoré; Uwe Ewald; Lena E Friberg
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Population Pharmacokinetic Modeling of Vancomycin in Thai Patients With Heterogeneous and Unstable Renal Function.

Authors:  Siriluk Jaisue; Cholatip Pongsakul; David Z D'Argenio; Pakawadee Sermsappasuk
Journal:  Ther Drug Monit       Date:  2020-12       Impact factor: 3.118

10.  Comparison of area under the curve for vancomycin from one- and two-compartment models using sparse data.

Authors:  Nyein Hsu Maung; Janthima Methaneethorn; Thitima Wattanavijitkul; Tatta Sriboonruang
Journal:  Eur J Hosp Pharm       Date:  2021-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.